IHCU:LSE:LSE-iShares S&P 500 Health Care Sector UCITS ETF USD (Acc) GBP (GBX)

ETF | Others |

Last Closing

USD 778.5

Change

+5.75 (+0.74)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

+0.42 (+0.20%)

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.08 (-0.58%)

USD 640.06B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.05 (-0.26%)

USD 640.06B
0R1I:LSE NVIDIA Corp.

+0.60 (+0.43%)

USD 618.20B
0R1G:LSE Home Depot Inc.

+1.96 (+0.53%)

USD 373.16B
PRJU:LSE Amundi Index Solutions - Amund..

-0.09 (-0.26%)

USD 269.13B
0QZK:LSE Coca-Cola Co.

+0.60 (+0.84%)

USD 266.08B
0QZO:LSE 0QZO

+0.13 (+0.11%)

USD 258.54B
0QZ3:LSE Qualcomm Inc.

+0.60 (+0.40%)

USD 202.26B
0R24:LSE Intel Corp.

+0.07 (+0.35%)

USD 196.14B

ETFs Containing IHCU:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.23% 10% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.23% 10% F 18% F
Trailing 12 Months  
Capital Gain -11.96% 8% B- 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.96% 8% B- 22% F
Trailing 5 Years  
Capital Gain 29.64% 43% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.64% 39% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 9.70% 61% D- 67% D+
Dividend Return 9.70% 60% D- 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.54% 69% C- 82% B
Risk Adjusted Return 101.73% 89% A- 94% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike